STARTRK-1: Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.
Study Details
Study Description
Brief Summary
Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3), ROS1 (coded by the gene ROS1), and ALK (coded by the gene ALK). Molecular alterations to one or more of these targets are present in several different tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), prostate cancer, papillary thyroid cancer, pancreatic cancer, and neuroblastoma. Patients with locally advanced or metastatic cancer with a detectable molecular alteration in targets of interest may be eligible for enrollment.
Phase 1 will assess safety and tolerability of entrectinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and efficacy will be assessed in the dose expansion portion of the study.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Entrectinib (RXDX-101) Oral entrectinib (RXDX-101) |
Drug: Entrectinib
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Dose-Limiting Toxicity (DLT) [28 days following first dose of entrectinib]
Determine dose-limiting toxicities of entrectinib.
- Maximum Tolerated Dose (MTD) [28 days following first dose of entrectinib]
Determine MTD of entrectinib
- Recommended Phase 2 Dose (RP2D) [Approx. 6 months]
Determine RP2D of entrectinib.
- Overall Response Rate (ORR) in Dose Expansion [Approx. 2 months]
Per RECIST v1.1 as assessed by Investigator.
Secondary Outcome Measures
- Plasma Concentrations of Entrectinib [Cycle 1 Days 1, 7, 14, 28]
- Disease Control [Approx. 2 years]
Per RECIST v1.1 as assessed by Investigator.
- Duration of Response [Approx. 2 years]
Per RECIST v1.1 as assessed by Investigator.
- Overall Survival (OS) [Approx. 2 years]
- Progression-Free Survival (PFS) [Approx. 2 years]
Eligibility Criteria
Criteria
Key Inclusion Criteria:
-
Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors that have a NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alteration.
-
Measurable disease according to RECIST version 1.1.
-
Prior cancer therapy is allowed, including crizotinib, ceritinib, and investigational drugs.
-
Prior radiotherapy is allowed
-
Patients with controlled asymptomatic central nervous system involvement are allowed.
-
Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.
-
Adult patients age 18 years or older.
-
Life expectancy of at least 3 months.
Key Exclusion Criteria:
-
Current participation in another therapeutic clinical trial.
-
Prior treatment with entrectinib.
-
History of prolonged QTc interval (e.g., repeated demonstration of a QTc interval > 450 milliseconds).
-
History of additional risk factors for torsade de pointes (e.g., family history of long QT syndrome).
-
Known active infections (bacterial, fungal, viral including HIV positivity).
-
Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.
-
Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis.
-
Peripheral neuropathy ≥ Grade 2.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UC Irvine Medical Center | Orange | California | United States | 92868 |
| 2 | University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center | San Francisco | California | United States | 94158 |
| 3 | University Of Colorado | Aurora | Colorado | United States | 80045 |
| 4 | Georgetown University Medical Center | Washington | District of Columbia | United States | 20007 |
| 5 | Florida Cancer Specialists - Sarasota | Sarasota | Florida | United States | 34232 |
| 6 | Massachusetts General Hospital | Boston | Massachusetts | United States | 02114 |
| 7 | Memorial Sloan Kettering Cancer Center | New York | New York | United States | 10065 |
| 8 | Tennessee Oncology | Nashville | Tennessee | United States | 37203 |
| 9 | University of Texas M.D. Anderson Cancer Center | Houston | Texas | United States | 77030 |
| 10 | Samsung Medical Center | Seoul | Korea, Republic of | 06531 |
Sponsors and Collaborators
- Hoffmann-La Roche
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RXDX-101-01
- GO40784